Competitive Opioid Antagonists [MoA]: Side Effects & Safety Data for 2 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Competitive Opioid Antagonists [MoA] includes 2 drugs with a combined 1,164 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
2
Drugs in Class
1,164
Combined Reports
All Competitive Opioid Antagonists [MoA] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| NALBUPHINE | Nalbuphine Hydrochloride | 702 | 78 | 95 | 11.1% |
| BUTORPHANOL | Butorphanol Tartrate | 462 | 10 | 24 | 2.2% |
Common Side Effects in Competitive Opioid Antagonists [MoA] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Dependence | 329 | 56 |
| Drug hypersensitivity | 255 | 0 |
| Overdose | 211 | 48 |
| Drug ineffective | 98 | 1 |
| Death | 62 | 62 |
| Off label use | 47 | 1 |
| Product dose omission issue | 42 | 0 |
| Drug dependence | 41 | 6 |
| Nausea | 34 | 1 |
| Foetal exposure during pregnancy | 31 | 1 |